Septerna is a clinical-stage biotechnology company focused on drugs that target G protein-coupled receptors (GPCRs), a major class of cell-surface proteins. Its proprietary Native Complex Platform is designed to enable discovery of oral small-molecule candidates against GPCRs that have been difficult to drug. The pipeline spans areas such as endocrinology, immunology and inflammation for patients with significant unmet medical needs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0.1 | — | -24.8 | — |
| Q3 2025 | 21.5 | — | 8.2 | — |
| Q4 2025 | 24.1 | — | -10.7 | — |
| Q1 2026 | 26.5 | — | -8.6 | — |
| Q2 2026 | 26.8 | 22,375.6% | -13 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Trevi Therapeutics, Inc. (TRVI), Schrödinger, Inc. (SDGR), UroGen Pharma Ltd. (URGN), Vir Biotechnology, Inc. (VIR), Braveheart Bio, Inc. (BRVE), Happen, Inc. (HAPN)